{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:06Z","timestamp":1793806146115,"version":"4.6.1"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Scientific Research Foundation of Guangxi Health Commission","award":["S2022142"],"award-info":[{"award-number":["S2022142"]}]},{"name":"the Scientific Research Foundation of Guangxi Health Commission","award":["S2020007"],"award-info":[{"award-number":["S2020007"]}]},{"name":"the Scientific Research Foundation of Guangxi Health Commission","award":["Z20211087"],"award-info":[{"award-number":["Z20211087"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bivalirudin and heparin are commonly employed anticoagulants in percutaneous coronary intervention (PCI) for patients diagnosed with acute coronary syndrome (ACS). This meta-analysis aimed to compare the safety and efficacy of bivalirudin and heparin in patients with ACS undergoing PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) and cohort studies comparing bivalirudin with heparin in patients with ACS undergoing PCI. The outcomes included all-cause mortality, cardiovascular mortality, major bleeding, major adverse cardiovascular events (MACEs), net adverse clinical events, myocardial infarction (MI), stent thrombosis (ST), and stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      This study included 11 RCTs and 17 cohort studies, encompassing 584,249 patients. Among in-hospital outcomes, bivalirudin was found to significantly reduce the incidence of all-cause mortality (relative risk [RR]\u2005=\u20050.86, 95% confidence interval [CI]: 0.84\u20130.88,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%) and major bleeding (RR\u2005=\u20050.74, 95% CI: 0.62\u20130.88,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200551%) compared with heparin, while there were no significant differences in MACEs, MI, ST, and stroke. Among 30-day follow-up outcomes, bivalirudin was found to significantly reduce the incidence of all-cause mortality (RR\u2005=\u20050.85, 95% CI: 0.76\u20130.95,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.006,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200524%), cardiovascular mortality (RR\u2005=\u20050.81, 95% CI: 0.70\u20130.94,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.004,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20051%), major bleeding (RR\u2005=\u20050.59, 95% CI: 0.49\u20130.72,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200567%), and net adverse clinical events (RR\u2005=\u20050.79, 95% CI: 0.70\u20130.89,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200555%) compared with heparin, while there were no significant differences in MACEs, MI, ST, and stroke.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis suggests that bivalirudin may offer advantages over heparin in reducing in-hospital and 30-day mortality and major bleeding in patients with ACS undergoing PCI, with no significant differences in ischemic outcomes such as MACEs, MI, ST, or stroke. These findings suggest that bivalirudin may be a reasonable alternative to heparin in selected patients, but more large-scale, long-term RCTs are needed to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050046","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:00:34Z","timestamp":1790359234000},"page":"e50046","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome"],"prefix":"10.1097","volume":"105","author":[{"given":"Chen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzi","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7209-0142","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"04291","DOI":"10.7189\/jogh.15.04291","article-title":"Global, regional, and national burden of ischaemic heart disease from 1990 to 2021: a comprehensive analysis based on the Global Burden of Disease study 2021.","volume":"15","author":"Liu","year":"2025","journal-title":"J Glob Health"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.carrev.2023.10.014","article-title":"Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.","volume":"61","author":"Al-Abdouh","year":"2024","journal-title":"Cardiovasc Revasc Med"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-025-02782-7","article-title":"The efficacy and safety of bivalirudin and heparin in patients with acute coronary syndrome: a systematic review and meta-analysis.","volume":"14","author":"Zhai","year":"2025","journal-title":"Syst Rev"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document.","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"e19064","DOI":"10.1097\/MD.0000000000019064","article-title":"Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes.","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-20261104","first-page":"1139","article-title":"Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"22","author":"Matar","year":"2006","journal-title":"Can J Cardiol"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction.","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.carrev.2008.12.005","article-title":"Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb\/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.","volume":"10","author":"Bonello","year":"2009","journal-title":"Cardiovasc Revasc Med"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/MCA.0b013e32832cff08","article-title":"Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.","volume":"20","author":"Cortese","year":"2009","journal-title":"Coron Artery Dis"},{"key":"R16-20261104","first-page":"513","article-title":"Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.","volume":"76","author":"Feldman","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jcin.2010.03.015","article-title":"Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) registry.","volume":"3","author":"Lopes","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajem.2010.09.010","article-title":"Prehospital treatment of patients with acute myocardial infarction with bivalirudin.","volume":"30","author":"Hirschl","year":"2012","journal-title":"Am J Emerg Med"},{"key":"R20-20261104","first-page":"614","article-title":"Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.","volume":"82","author":"Sardi","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4244\/EIJV9I1A17","article-title":"Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.","volume":"9","author":"Shelton","year":"2013","journal-title":"EuroIntervention"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI.","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"R23-20261104","first-page":"268","article-title":"Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry.","volume":"3","author":"Sciahbasi","year":"2014","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes.","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/FJC.0000000000000411","article-title":"Effectiveness and safety of bivalirudin during percutaneous coronary intervention in acute coronary syndrome in the real world: CARTAGOMAX study.","volume":"68","author":"Casc\u00f3n-P\u00e9rez","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jcin.2016.09.020","article-title":"Use and effectiveness of bivalirudin versus unfractionated heparin for percutaneous coronary intervention among patients with ST-segment elevation myocardial infarction in the United States.","volume":"9","author":"Secemsky","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/joic.12397","article-title":"Bivalirudin versus heparin and provisional GP IIb\/IIIa inhibitors in patients treated for ST-segment elevation myocardial infarctions: comparison of outcomes in a \u201creal-world\u201d setting.","volume":"30","author":"Fach","year":"2017","journal-title":"J Interv Cardiol"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.hlc.2016.12.019","article-title":"Comparison of safety and efficacy of unfractionated heparin versus bivalirudin in patients undergoing percutaneous coronary intervention.","volume":"26","author":"Rehmani","year":"2017","journal-title":"Heart Lung Circ"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction.","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"110758","DOI":"10.1016\/j.biopha.2020.110758","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.","volume":"130","author":"Zhang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"932054","DOI":"10.3389\/fcvm.2022.932054","article-title":"Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a multicenter prospective cohort study.","volume":"9","author":"Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R34-20261104","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"R35-20261104","doi-asserted-by":"crossref","first-page":"10760296221077973","DOI":"10.1177\/10760296221077973","article-title":"Safety of bivalirudin combined with ticagrelor in the emergency PCI in patients with acute ST-segment elevation myocardial infarction.","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"R36-20261104","doi-asserted-by":"crossref","first-page":"e13013","DOI":"10.1590\/1414-431x2023e13013","article-title":"Bivalirudin vs heparin in cardiac-cerebral ischemic and bleeding events among Chinese STEMI patients during percutaneous coronary intervention: a retrospective cohort study.","volume":"56","author":"Bai","year":"2023","journal-title":"Braz J Med Biol Res"},{"key":"R37-20261104","first-page":"4246","article-title":"Comparison of short-to medium-term ischemia and bleeding risks between unfractionated heparin and bivalirudin in patients with acute coronary syndrome after PCI.","volume":"104","author":"Hou","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R38-20261104","first-page":"96","article-title":"The effects of bivalirudin and ordinary heparin on the incidence of bleeding events and the level of inflammation after interventional therapy for acute myocardial infarction.","volume":"31","author":"Wu","year":"2025","journal-title":"Altern Ther Health Med"},{"key":"R39-20261104","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"R40-20261104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"R41-20261104","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/eurheartj\/ehac312","article-title":"Cardiovascular meta-analyses: fool\u2019s gold or gold for fools?","volume":"43","author":"Biondi-Zoccai","year":"2022","journal-title":"Eur Heart J"},{"key":"R42-20261104","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting.","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"R43-20261104","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1037\/1082-989X.8.3.243","article-title":"How meta-analysis increases statistical power.","volume":"8","author":"Cohn","year":"2003","journal-title":"Psychol Methods"},{"key":"R44-20261104","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.jacc.2025.04.050","article-title":"ACS guidelines: bridging the transatlantic divide.","volume":"85","author":"Coughlan","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R45-20261104","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","article-title":"Antithrombotic therapy for patients with STEMI undergoing primary PCI.","volume":"14","author":"Franchi","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"R46-20261104","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","article-title":"Bivalirudin.","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"key":"R47-20261104","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/vhrm.2006.2.4.357","article-title":"Bivalirudin in percutaneous coronary intervention.","volume":"2","author":"Lehman","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"R48-20261104","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin.","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R49-20261104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-017-0082-x","article-title":"The rise and fall of anticoagulation with bivalirudin during percutaneous coronary interventions: a review article.","volume":"6","author":"Andreou","year":"2017","journal-title":"Cardiol Ther"},{"key":"R50-20261104","doi-asserted-by":"crossref","first-page":"108S","DOI":"10.1592\/phco.24.12.108S.36114","article-title":"Challenges in variation and responsiveness of unfractionated heparin.","volume":"24","author":"Francis","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R51-20261104","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"R52-20261104","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/VHRM.S2455","article-title":"Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.","volume":"4","author":"Ramana","year":"2008","journal-title":"Vasc Health Risk Manag"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:01:35Z","timestamp":1793804495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050046"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":51,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050046","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-03-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}